Article
Oncology
Ryunosuke Nakagawa, Hiroaki Iwamoto, Tomoyuki Makino, Suguru Kadomoto, Hiroshi Yaegashi, Masashi Iijima, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami
Summary: This study investigated the safety of pegfilgrastim during BEP therapy. The results showed that compared to using short-acting G-CSF, the use of pegfilgrastim significantly increased the peak neutrophil count, reduced the incidence and duration of grade 3-4 neutropenia, and had no significant difference in the incidence of febrile neutropenia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Samuel A. Funt, Deaglan J. McHugh, Stephanie Tsai, Andrea Knezevic, Devon O'Donnell, Sujata Patil, Deborah Silber, Maria Bromberg, Maryann Carousso, Victor E. Reuter, Brett S. Carver, Joel Sheinfeld, Robert J. Motzer, Dean F. Bajorin, George J. Bosl, Darren R. Feldman
Summary: The study analyzed the outcomes of 944 patients with good-risk germ cell tumors treated with EPx4 between 1982 and 2016. The results showed that EPx4 is highly effective and well tolerated, with a favorable response rate and disease-specific survival of 98%. Full-dose administration of etoposide and cisplatin and complete resection of residual disease lead to optimal outcomes. EPx4 should be recommended for certain patient groups at increased risk for bleomycin pulmonary toxicity and during ongoing transmission of severe acute respiratory syndrome coronavirus 2.
Article
Oncology
Ran Chu, Penglin Liu, Jingying Chen, Xiaodong Cheng, Kezhen Li, Yanci Che, Jianliu Wang, Li Li, Xi Zhang, Shu Yao, Li Song, Ying Zhao, Changzhen Huang, Ying Xue, Xiyu Pan, Junting Li, Zhongshao Chen, Jie Jiang, Beihua Kong, Kun Song
Summary: This study evaluated the impact of BEP and PC chemotherapy regimens on fertility and prognostic outcomes in MOGCT patients who underwent FSS. The results showed that there were no significant differences in fertility outcome, disease-free survival, and overall survival between the BEP and PC groups. It can be concluded that the PC regimen is as safe as the BEP regimen for preserving fertility and clinical prognosis in MOGCT patients.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Dennis M. Timmerman, Thomas F. Eleveld, Ad J. M. Gillis, Carlijn C. Friedrichs, Sanne Hillenius, Tessa L. Remmers, Sruthi Sriram, Leendert H. J. Looijenga
Summary: Germ cell tumors (GCTs) have varying responses to platinum-based chemotherapy depending on their anatomical origin, with mediastinal GCTs showing resistance compared to testicular GCTs. TP53 mutations may play a role in causing cisplatin resistance in mediastinal GCTs, suggesting a potential target for treatment. The study provides insights into the underlying mechanisms of TP53 mutant and mediastinal GCTs for alternative treatment approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Andre van Helvoort Lengert, Leticia do Nascimento Braga Pereira, Eduardo Ramos Martins Cabral, Izabela Natalia Faria Gomes, Lais Machado de Jesus, Maria Fernanda Santiago Goncalves, Aline Oliveira da Rocha, Tiago Alexandre Tassinari, Luciane Sussuchi da Silva, Ana Carolina Laus, Daniel Onofre Vidal, Mariana Tomazini Pinto, Rui Manuel Reis, Luiz Fernando Lopes
Summary: This study explored new strategies for treating cisplatin-resistant testicular germ cell tumors (TGCTs). Differential mRNA expression profiles were evaluated in a CDDP-resistant cell line and a parental cell line. The proteasome inhibitor MG-132 demonstrated cytotoxic activity and enhanced the sensitivity of the cell lines to cisplatin, increasing apoptosis.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Article
Biotechnology & Applied Microbiology
Ming Wang, Lianna Shen, Xiaohong Xu, Wei Duan, Jinwei Miao, Weimin Kong, Li Su, Yumei Wu
Summary: This retrospective study on the use of BEP chemotherapy in 95 patients with gestational trophoblastic neoplasia (GTN) showed that BEP regimen was effective in treating GTN, with good tolerability and no safety concerns on patients' fertility.
BIOMED RESEARCH INTERNATIONAL
(2021)
Article
Cardiac & Cardiovascular Systems
Kenneth A. Kesler, Amanda R. Stram, Lava R. Timsina, Mark W. Turrentine, John W. Brown, Lawrence H. Einhorn
Summary: In the treatment of primary mediastinal nonseminomatous germ cell tumors, avoiding bleomycin-containing chemotherapy is important. Pre-and post chemotherapy pathology and postoperative serum tumor markers are independent predictors of long-term survival.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Medicine, Research & Experimental
Mojtaba Moradi, Nader Goodarzi, Azita Faramarzi, Hadi Cheraghi, Amir Hossein Hashemian, Cyrus Jalili
Summary: Melatonin protects the testes against BEP-induced testicular damage by restoring spermatogenesis, improving testosterone levels, and ameliorating oxidative stress. Furthermore, melatonin therapy suppresses BEP-evoked apoptosis in testes, suggesting its potential as a clinical therapy against BEP-associated gonadotoxicity and male sub/infertility.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Andreas Hiester, Anna Fingerhut, Gunter Niegisch, Roswitha Siener, Susanne Krege, Hans-Ulrich Schmelz, Klaus-Peter Dieckmann, Axel Heidenreich, Peter Kwasny, Maik Pechoel, Jan Lehmann, Sabine Kliesch, Kai-Uwe Koehrmann, Rolf Fimmers, Volker Loy, Christian Wittekind, Michael Hartmann, Peter Albers
Summary: After 13 years of follow-up, it was observed that one cycle of adjuvant BEP remains superior to RPLND in preventing recurrence in patients with testicular CS I NSGCT, showing good tolerance without significant long-term toxicities.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biology
Hale Bayram, Yaprak Donmez Cakil, Mustafa Erinc Sitar, Gamze Demirel, Belgin Selam, Mehmet Cincik
Summary: Chemotherapeutic agents used in the treatment of testicular cancer cause damage to healthy tissues. However, the use of glutathione can protect testicular histomorphology and sperm DNA integrity. Glutathione can alleviate the detrimental effects of chemotherapy on male reproductive functions.
Article
Developmental Biology
Peter K. Nicholls, David C. Page
Summary: Germ cells commit to gametogenesis after colonizing the gonads, and germ cell tumors may originate from cells that failed to undergo germ cell determination. The diversity of cell types in these tumors reflects the developmental potential of migratory PGCs.
Article
Oncology
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, David Niehaus, Inken Dralle-Filiz, Cord Matthies, Tamas Dienes, Stefanie Zschaebitz, Pia Paffenholz, Tanja Gschliesser, Renate Pichler, Michal Mego, Pia Bader, Friedemann Zengerling, Julia Heinzelbecker, Philipp Krausewitz, Susanne Krege, Gaetano Aurilio, Cem Aksoy, Marcus Hentrich, Christoph Seidel, Peter Toerzsoek, Tim Nestler, Matthaeus Majewski, Andreas Hiester, Tomas Buchler, Sonia Vallet, Hana Studentova, Sandra Schoenburg, Dora Niedersuess-Beke, Julia Ring, Emanuela Trenti, Axel Heidenreich, Christian Wuelfing, Hendrik Isbarn, Uwe Pichlmeier, Martin Pichler
Summary: The 1xBEP regimen is a safe treatment for patients with CS1 NSGCT, with a low relapse rate and a high cure rate for relapses.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Meerim Park, Jin Kyung Suh, Jun Ah Lee, Hyeon Jin Park, Eun Young Park, Chong Woo Yoo, Myong Cheol Lim, Sang-Yoon Park, Byung Kiu Park
Summary: A study on malignant ovarian germ cell tumors (MOGCTs) in patients under the age of 39 found that reducing the dose of bleomycin did not adversely affect survival, while rapid normalization of tumor markers was associated with better outcomes.
Article
Oncology
M. Mego, D. Svetlovska, V De Angelis, K. Kalavska, P. Lesko, M. Makovnik, J. Obertova, Z. Orszaghova, P. Palacka, M. Reckova, K. Rejlekova, Z. Sycova-Mila, J. Mardiak, M. Chovanec
Summary: This study investigated the efficacy and toxicity of ALDH inhibitor disulfiram in combination with cisplatin in patients with multiple relapsed/refractory GCTs. The results showed limited efficacy of disulfiram in restoring sensitivity to cisplatin in multiple relapsed/refractory GCTs.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Nianyu Xue, Guoyao Wang, Shengmin Zhang, Yijun Lu
Summary: Unlike younger patients, seminoma is not common in patients with primary testicular tumors over the age of 50. The diagnostic value of conventional ultrasonography and contrast-enhanced ultrasonography (CEUS) in these patients was compared. The CEUS method showed higher accuracy in distinguishing between germ cell tumors and non-germ cell tumors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
David Mizrahi, David Goldstein, Terry Trinh, Tiffany Li, Hannah C. Timmins, Michelle Harrison, Gavin M. Marx, Elizabeth J. Hovey, Craig R. Lewis, Michael Friedlander, Susanna B. Park
Summary: Neurotoxic chemotherapy may lead to low physical activity levels and interfere with physical activity among cancer survivors. Age, BMI, and CIPN are predictors of walking and moderate-vigorous physical activity.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Panagiotis A. Konstantinopoulos, Antonio Gonzalez-Martin, Felipe Melo Cruz, Michael Friedlander, Rosalind Glasspool, Domenica Lorusso, Christian Marth, Bradley J. Monk, Jae-Weon Kim, Patsy Hinson, Olga Ajipa, Vincent Pretre, Yu Han, Ursula A. Matulonis
Summary: This article describes a study investigating the combination of the specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib and the poly (adenosine diphosphateribose) polymerase (PARP) inhibitor olaparib in platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) patients without germline BRCA mutation. The study aims to improve the prognosis of patients with this condition.
Article
Oncology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Maintenance therapy with olaparib showed sustained progression-free survival benefit in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. After a 7-year follow-up, there was a clinically meaningful improvement in overall survival. The incidence of myelodysplastic syndrome and acute myeloid leukemia was low.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Azam Majidi, Renhua Na, Susan J. Jordan, Anna DeFazio, Andreas Obermair, Michael Friedlander, Peter Grant, Penelope M. Webb
Summary: This study investigated the association between nonsteroidal antiinflammatory drug (NSAID) use and 5-year cancer-specific survival in Australian women with ovarian cancer. The results showed that frequent use of NSAIDs, including aspirin and nonaspirin NSAIDs, was associated with better survival compared to nonusers and infrequent users. These findings suggest that NSAID use might improve ovarian cancer survival.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Obstetrics & Gynecology
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Summary: Due to nonspecific symptoms and inadequate screening, ovarian cancer is often diagnosed at an advanced stage, resulting in low survival rates. The PARP inhibitor olaparib has shown significant benefits in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. The SOLO1/GOG 3004 study found that olaparib treatment resulted in prolonged progression-free survival up to 2 years and showed potential overall survival benefits up to 7 years. However, further analysis is needed to confirm the statistical significance.
OBSTETRICAL & GYNECOLOGICAL SURVEY
(2023)
Article
Oncology
Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill
Summary: Until recently, the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have improved outcomes for some women, but determining which women will respond is important. This study aimed to find markers to better predict response to immunotherapy. Tumor-associated inflammatory cells were found to have the strongest association with response. A novel algorithm using optimal cutoff points was able to identify non-responders with high sensitivity. Further validation is needed.
Article
Oncology
David Tan, Noriko Fujiwara, Keiichi Fujiwara, Philip Beale, Jae-Weon Kim, Joseph Ng, Se Ik Kim, Alison Evans, Byoung-Gie Kim
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, Susanna B. Park
Summary: This study aims to provide interpretation guidelines for validated CIPN PROMs, allowing estimation of thresholds to identify clinically relevant symptoms.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2023)
Article
Oncology
Omali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, Sivatharsny Srirangan, Cristina Mapagu, Judy Kirk, Paul R. Harnett, Rosemary L. Balleine, David D. L. Bowtell, Goli Samimi, Alison H. Brand, Deborah J. Marsh, Philip Beale, Lyndal Anderson, Natalie Bouantoun, Pamela Provan, Susan J. Ramus, Anna DeFazio, Michael Friedlander
Summary: The somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes in older patients (>=70 years) with high-grade serous ovarian carcinomas (HGSC) are not well-characterized due to low testing rates. However, the overall frequency of somatic PVs in HR-related genes is similar in older and younger patients, highlighting the importance of somatic testing regardless of age.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Soseul Sung, Youjin Hong, Byoung-Gie Kim, Ji-Yeob Choi, Jae Weon Kim, Sang-Yoon Park, Jae-Hoon Kim, Yong-man Kim, Jong-Min Lee, Tae Jin Kim, Sue K. K. Park
Summary: This study aimed to verify the association between ovarian cancer (OC) and reproductive- and lifestyle-related risk factors stratified by the subtype of OC. The results showed that smoking was positively associated with high-grade serous (HGS) OC, alcohol consumption was positively associated with mucinous type (MUC), and obesity was associated with clear cell type (CLC). Further, spontaneous abortion was negatively associated with CLC, while tubal ligation, hysterectomy, and oophorectomy were associated with decreased risk of HGS. Early menarche was strongly associated with increased risk of CLC. Additionally, childbirth, oral contraceptives, and hormone replacement therapy were negatively associated with OC.
Article
Oncology
Michael Friedlander, Linda Mileshkin, Janine Lombard, Sophia Frentzas, Bo Gao, Michelle Wilson, Tarek Meniawy, Sally Baron-Hay, Karen Briscoe, Nicole McCarthy, Christos Fountzilas, Andres Cervantes, Ruimin Ge, John Wu, Alexander Spira
Summary: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in previously treated advanced solid tumours. The study showed that pamiparib plus tislelizumab demonstrated a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR observed in triple-negative breast cancer cases.
BRITISH JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Mallory J. DiVincenzo, Colin D. Angell, Lorena P. Suarez-Kelly, Casey Ren, Zoe Barricklow, Maribelle Moufawad, Paolo Fadda, Lianbo Yu, Floor J. Backes, Kari Ring, Anne Mills, Craig Slingluff, Catherine Chung, Alejandro A. Gru, William E. E. Carson III
Summary: This study investigates the expression profiles of microRNAs (miRNAs) and messenger RNAs (mRNAs) in melanomas from gynecologic sites (MOGS) and identifies specific dysregulation patterns. The findings suggest that miRNAs play a role in mediating gene expression in MOGS and reveal potential therapeutic targets.
Article
Obstetrics & Gynecology
Brandon Fox, Floor Backes
GYNECOLOGIC ONCOLOGY REPORTS
(2023)